Sermorelin 5mg research peptide UK is the advanced-format native GHRH analogue for established UK laboratory programmes requiring multi-arm longitudinal pulsatile GH pharmacokinetic studies. ≥98% purity. Janoshik tested. Same-day UK dispatch before 4pm. For research use only.
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
SERMORELIN 5mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
Sermorelin 5 mg:
https://janoshik.com/tests/125393-Sermorelin_5mg_YK2N4A7Q3EZS
Research use only • UK dispatch • Orders before 4pm ship same day • Secure checkout
Sermorelin 5mg Research Peptide UK
Sermorelin 5mg is the advanced-format version of the most physiologically representative GHRH research analogue. Identical compound to Sermorelin 2mg — C149H246N44O42S, 3,357.93 Da, GRF 1-29 NH2, unmodified 29-amino acid GHRH sequence, approximately 12-minute in vitro half-life — providing the compound volume for multi-arm pharmacokinetic studies, longitudinal pulsatile dynamics investigations, and comparative GHRH analogue protocols that the 2mg format may be less suited for larger-scale experimental designs at the required scale.
The research case for sermorelin 5mg research peptide builds on programme scale rather than compound differences. Once Sermorelin 2mg has validated the experimental design and confirmed assay conditions in pilot studies, the 5mg format provides extended single-batch consistency and full dose-response gradient capability across multiple treatment arms. This single-batch consistency is critical when comparing pulse amplitude, pulse frequency, and clearance kinetics across multiple time points where any inter-batch molecular variability would compromise the precision of pulsatile dynamics data.
Sermorelin 5mg is particularly suited to three-analogue GHRH comparison programmes that require equivalent volume across all three compound arms. Running sermorelin 5mg (unmodified, approximately 12 minutes half-life) alongside CJC-1295 Without DAC 10mg (DPP-IV resistant modifications, approximately 30 minutes) and Tesamorelin 10mg (full 44-amino acid sequence, N-terminal modified) provides a comprehensive structural comparison toolkit. The 5mg format matches the volume capacity of the 10mg GHRH analogues when accounting for the lower dosing requirements typical of pulsatile kinetics protocols.
For combined GHRP protocols alongside sermorelin, Ipamorelin 10mg targets GHS-R1a independently of the GHRHR pathway, allowing dual-pathway GH research. For downstream IGF-1 axis research complementing GHRH studies, IGF-1 LR3 1mg provides the growth factor probe for the downstream signalling cascade.
Note on DPP-IV sensitivity: sermorelin’s moderate susceptibility to DPP-IV degradation means reconstituted solution should be aliquoted immediately and used within experimental timelines. Bacteriostatic water is the recommended reconstitution solvent.
All batches tested by Janoshik. HPLC greater than or equal to 98%. LC-MS confirmed. Verifiable CoA.
WADA Status: Not suitable for clinical, and diagnostic uses.
DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.
A curated entry point for buyers comparing quality, documentation, and availability.
UK same-day dispatch – PCI-
compliant payments –
Laboratory research only
© 2026 by Ascend Peptides Uk.
